Latvia MGI Tech (MGI Latvia) is a subsidiary of MGI Tech Co., Ltd. (MGI), a global leader in life science innovation, established in 2016 and now operating in more than 50 countries and regions serving more than 1000 customers worldwide. MGI is is committed to enabling effective and affordable healthcare solutions for all. Based on its proprietary technology, MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare. MGI’s multi-omics platforms include reagents, medical imaging, laboratory automation, and genetic sequencing. MGI solutions are used in such sectors as scientific research, agriculture, and healthcare. Recently the company's equipment has been contributing to increasing Covid-19 testing capabilities in multiple countries around the world including Sweden, Denmark, Italy, Spain, Australia, Canada, the United States, South Korea, Thailand, Israel, and beyond since the first Covid-19 outbreak in early 2020. MGI Latvia was established in Riga in late 2019, and acts as a hub of Research and Development, production, logistics and specialised training for MGI’s business development in Europe and other international regions. The 7,000 square-metre facility has a Global Product Application Demo Centre and a state-of-art Sequencing Centre. MGI Latvia focuses on providing effective real-time, comprehensive, life-long solutions for Europe andand other international regions. MGI Latviahas been the largest foreign investment in the biotechnology sector in Latvia and the Baltics to date, exceeding 15 million euros. MGI Latvia has formed extensive collaborations with local research centres. One of the key collaborators is the Latvian Biomedical Research and Study Center. The company participates in a number of major national projects including ERDF, and Horizon 2020 projects. MGI Latvia is a member of the Foreign Investors' Council in Latvia and the Latvian Chamber of Commerce and Industry.